Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01826370
NCT01826370
Terminated
Not Applicable

A Post-Marketing Surveillance Study on the Safety, Tolerability and Efficacy of Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim51 sites in 1 country678 target enrollmentMay 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetes Mellitus, Type 2
InterventionsLinagliptin
DrugsLinagliptin

Overview

Phase
Not Applicable
Intervention
Linagliptin
Conditions
Diabetes Mellitus, Type 2
Sponsor
Boehringer Ingelheim
Enrollment
678
Locations
51
Primary Endpoint
Frequency of Adverse Events and Serious Adverse Events
Status
Terminated
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus (DM) within the study duration of 24 weeks.

Registry
clinicaltrials.gov
Start Date
May 2012
End Date
October 2013
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Linagliptin

Intervention: Linagliptin

Outcomes

Primary Outcomes

Frequency of Adverse Events and Serious Adverse Events

Time Frame: Week 24

Frequency of adverse events and serious adverse events in an actual clinical setting, including hypoglycemic events.

Secondary Outcomes

  • Change From Baseline to Week 24 of HbA1c(Baseline and 24 weeks)
  • Change From Baseline to Week 24 of Fasting Blood Sugar(Baseline and 24 weeks)

Study Sites (51)

Loading locations...

Similar Trials

Terminated
Not Applicable
A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckUnresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckLA SCCHN
NCT01303237Merck KGaA, Darmstadt, Germany88
Completed
Phase 4
Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean ChildrenHaemophilus Influenzae Type B Infection
NCT01404962Novartis Vaccines764
Completed
Not Applicable
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)Relapsing-Remitting Multiple Sclerosis
NCT01142492Merck KGaA, Darmstadt, Germany403
Completed
Not Applicable
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical PracticeHIV Infections
NCT01524900Boehringer Ingelheim398
Completed
Not Applicable
Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®Breast Neoplasm
NCT03445637Pfizer552